ArticlePloS one2025
The absence or the pharmacological blockade of the aryl hydrocarbon receptor promotes neuroprotection in the hippocampus after an ischemic insult.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aryl hydrocarbon receptor (AhR) is a transcription factor that acts as a nuclear receptor mediating xenobiotic metabolism and environmental responses. Recent evidence suggests that the AhR is implicated in maintaining homeostasis or triggering pathological effects by modulating different physiological responses in the nervous system. However, the underlying mechanisms of the AhR-induced effects in the hippocampus remain unclear. Herein, we report a previously unknown role for the AhR in the pathogenesis of a transient global ischemic insult. Comparative analysis of the expression of HIF-1α, nNOS, iNOS, IL6, KAT II, and claudin 5 in the hippocampus of AhR+/+ and AhR-/- mice after bilateral common carotid artery occlusion revealed differential modulation. We report that AhR-/- mice significantly reduced the blood-brain barrier (BBB) dysfunction and neuronal death in hippocampus-CA1 caused by the ischemic insult, inducing neuroprotection. In addition, blocking the AhR with Resveratrol (a competitive antagonist) decreased neuronal degeneration and preserved the integrity of the BBB in the hippocampus associated with a neuroprotective effect. In summary, we showed that the AhR is an essential regulator for maintaining the BBB in the hippocampus and responds to inflammatory conditions and oxidative stress; further pharmacological targeting of AhR signaling may reduce the pathologic changes caused by an ischemic insult in the hippocampus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.